Absci Corp — Investor Relations & Filings
Filings indexed
315
across all filing types
Latest filing
2026-04-22
Annual Report
Country
US
United States of America
Listing
US
ABSI
Absci Corp. is a generative AI drug creation company focused on developing biologic medicines. The company's Integrated Drug Creation Platform combines artificial intelligence with scalable wet lab technologies to design and validate novel therapeutics. This platform operates through iterative cycles of data generation, AI model training, de novo design of biologics like antibodies, and experimental validation. Absci's capabilities also include AI-enabled target discovery using a proprietary 'Reverse Immunology' approach. As a clinical-stage company, it advances an internal pipeline and collaborates with pharmaceutical partners to accelerate the development of differentiated biologics for patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| ARS - Absci Corp (0001672688) (Filer) | 2026-04-22 | English | |
| SCHEDULE 13D/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | |
| SCHEDULE 13G/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | |
| S-8 - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | |
| 10-K - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | |
| 4 - ABSCI CORP (0001672688) (Filer) | 2026-03-03 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 35398073 | ARS - Absci Corp (0001672688) (Filer) | 2026-04-22 | English | ||
| 33052408 | SCHEDULE 13D/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | ||
| 33048944 | SCHEDULE 13G/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | ||
| 33035253 | S-8 - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | ||
| 33035179 | 10-K - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | ||
| 32896336 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-03-03 | English | ||
| 32896337 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-03-03 | English | ||
| 32896338 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-02-25 | English | ||
| 32896339 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-02-04 | English | ||
| 32896340 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-02-04 | English | ||
| 31233301 | 4 Filing | 2026-02-04 | English | ||
| 31233143 | 4 Filing | 2026-02-04 | English | ||
| 31233276 | SCHEDULE 13G Filing | 2026-01-30 | English | ||
| 31233114 | 4 Filing | 2026-01-30 | English | ||
| 12952145 | 8-K | 2026-01-14 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Linical Co., Ltd.
A global CRO providing a full spectrum of drug development …
|
2183 | JP | Professional, scientific and te… |
|
Lipigon Pharmaceuticals AB
A clinical-stage company developing therapeutics for lipid-…
|
LPGO | SE | Professional, scientific and te… |
|
Lipum AB
Clinical-stage biopharma developing novel treatments for ch…
|
LIPUM | SE | Professional, scientific and te… |
|
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Clinical-stage pharma company developing PP2A inhibitors to…
|
LIXT | US | Professional, scientific and te… |
|
Lunai Bioworks Inc.
Pre-clinical biotech company using AI for drug discovery an…
|
RENB | US | Professional, scientific and te… |
|
LYSOGENE
A former clinical-stage biotech that developed gene therapi…
|
LYS | FR | Professional, scientific and te… |
|
MaaT Pharma
A clinical-stage biotech developing microbiome-based therap…
|
MAAT | FR | Professional, scientific and te… |
|
Many Bright Ideas Technologies Inc.
Acquires, develops, and commercializes IP, emphasizing alte…
|
MBI.H | CA | Professional, scientific and te… |
|
MapLight Therapeutics, Inc.
Develops targeted therapies for CNS disorders using circuit…
|
MPLT | US | Professional, scientific and te… |
|
Marvel Biosciences Corp.
Developing transformative treatments for complex neurologic…
|
MRVL | CA | Professional, scientific and te… |
Absci Corp via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32931/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32931 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32931 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32931 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32931}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Absci Corp (id: 32931)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.